Kilian Scott, Surrey Aaron, McCarron Weston, Mueller Kristen, Wessman Brian Todd
Department of Emergency Medicine, Washington University in St Louis, School of Medicine, Barnes-Jewish Hospital, St Louis, Missouri, United States of America.
Division of Critical Care Medicine, Department of Anesthesiology, Washington University in St Louis, School of Medicine, St Louis, Missouri, United States of America.
Indian J Crit Care Med. 2022 Jul;26(7):811-815. doi: 10.5005/jp-journals-10071-24243.
Septic shock is commonly treated in the emergency department (ED) with vasopressors. Prior data have shown that vasopressor administration through a peripheral intravenous line (PIV) is feasible.
To characterize vasopressor administration for patients presenting to an academic ED in septic shock.
Retrospective observational cohort study evaluating initial vasopressor administration for septic shock. ED patients from June 2018 to May 2019 were screened. Exclusion criteria included other shock states, hospital transfers, or heart failure history. Patient demographics, vasopressor data, and length of stay (LOS) were collected. Cases were grouped by initiation site: PIV, ED placed central line (ED-CVL), or tunneled port/indwelling central line (Prior-CVL).
Of the 136 patients identified, 69 were included. Vasopressors were initiated via PIV in 49%, ED-CVL in 25%, and prior-CVL in 26%. The time to initiation was 214.8 minutes in PIV and 294.7 minutes in ED-CVL ( = 0.240). Norepinephrine predominated all groups. No extravasation or ischemic complications were identified with PIV vasopressor administration. Twenty-eight-day mortality was 20.6% for PIV, 17.6% for ED-CVL, and 61.1% for prior-CVL. Of 28-day survivors, ICU LOS was 4.44 for PIV and 4.86 for ED-CVL ( = 0.687), while vasopressor days were 2.26 for PIV and 3.14 for ED-CVL ( = 0.050).
Vasopressors are being administered via PIVs for ED septic shock patients. Norepinephrine comprised the majority of initial PIV vasopressor administration. There were no documented episodes of extravasation or ischemia. Further studies should look at the duration of PIV administration with potential avoidance of central venous cannulation altogether in appropriate patients.
Kilian S, Surrey A, McCarron W, Mueller K, Wessman BT. Vasopressor Administration via Peripheral Intravenous Access for Emergency Department Stabilization in Septic Shock Patients. Indian J Crit Care Med 2022;26(7):811-815.
脓毒性休克通常在急诊科(ED)使用血管升压药进行治疗。既往数据表明,通过外周静脉通路(PIV)给予血管升压药是可行的。
描述脓毒性休克患者在学术性急诊科接受血管升压药治疗的情况。
一项回顾性观察队列研究,评估脓毒性休克患者初始血管升压药的使用情况。对2018年6月至2019年5月期间的急诊科患者进行筛查。排除标准包括其他休克状态、医院内转科或有心力衰竭病史。收集患者人口统计学资料、血管升压药数据及住院时间(LOS)。病例按置管部位分组:PIV、急诊科置入中心静脉导管(ED-CVL)或隧道式端口/留置中心静脉导管(Prior-CVL)。
在确定的136例患者中,69例被纳入研究。49%的患者通过PIV开始使用血管升压药,25%通过ED-CVL,26%通过Prior-CVL。PIV组开始用药时间为214.8分钟,ED-CVL组为294.7分钟(P = 0.240)。所有组均以去甲肾上腺素为主。PIV给予血管升压药未发现外渗或缺血并发症。PIV组28天死亡率为20.6%,ED-CVL组为17.6%,Prior-CVL组为61.1%。在28天存活患者中,PIV组ICU住院时间为4.44天,ED-CVL组为4.86天(P = 0.687),而PIV组血管升压药使用天数为2.26天,ED-CVL组为3.14天(P = 0.050)。
急诊科脓毒性休克患者通过PIV给予血管升压药。去甲肾上腺素是初始PIV血管升压药使用的主要药物。未记录到外渗或缺血事件。进一步研究应关注PIV给药的持续时间,并考虑在合适的患者中完全避免中心静脉置管。
Kilian S, Surrey A, McCarron W, Mueller K, Wessman BT. 通过外周静脉通路给予血管升压药以稳定脓毒性休克患者的急诊科病情。《印度重症医学杂志》2022;26(7):811 - 815。